-+ 0.00%
-+ 0.00%
-+ 0.00%

Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Concerning FDA Review And Advisory Committee Meeting - Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Barchart·07/29/2026 18:29:00
Listen to the news

LOS ANGELES, July 29, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ:CAPR) investors concerning the Company's possible violations of the federal securities laws.  

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.